Sarepta Therapeutics Inc (SRPT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.72B
Last updated: Nov 17, 2026 at 11:06 AM ET
Sarepta Therapeutics Inc (SRPT) Stock Forecast
Analysts expect Sarepta Therapeutics (SRPT) to earn $3.95 per share in the fiscal year ending Dec 31, 2026, on revenue of $1.86B. Of 24 analysts, 7 rate the stock Buy or Strong Buy, 12 Hold and 5 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 3 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 24 ratings average 3.00, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 29% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 7 | 29.2% |
| Hold | 12 | 50.0% |
| Sell | 3 | 12.5% |
| Strong Sell | 2 | 8.3% |
- Consensus
- Hold
- Total analysts
- 24
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus falls 62.5% and revenue estimates fall 25.8%.
- Fiscal year ending Dec 31, 2026
- $3.95
- EPS consensus, revenue $1.86B
- Fiscal year ending Dec 31, 2027
- $1.48
- EPS consensus, revenue $1.38B
- Next report
- Feb 23, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $3.95 | $2.05 to $5.03 | 11 | $1.86B | $1.80B to $1.89B | 20 |
| Dec 31, 2027 | $1.48 | -$0.30 to $3.47 | 11 | $1.38B | $856.94M to $1.79B | 20 |
Quarterly Estimates
The EPS consensus rises from -$0.37 for the quarter ending Dec 31, 2026 to $0.44 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.37 | -$1.53 to $0.21 | 24 | $360.44M | $294.75M to $400.47M | 22 |
| Mar 31, 2027 | $0.44 | -$0.02 to $0.96 | 6 | $357.09M | $320.70M to $383.90M | 11 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 1 upward and 6 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 3 |
| Fiscal year ending Dec 31, 2027 | 1 | 2 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 10.0% from $4.39.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $3.95 | $4.32 | $4.32 | $4.44 | $4.39 | -9.9% |
| Fiscal year ending Dec 31, 2027 | $1.48 | $2.45 | $2.41 | $2.57 | $2.60 | -42.9% |
| Quarter ending Mar 31, 2027 | $0.44 | $0.73 | $0.78 | $0.75 | $0.78 | -43.9% |
Frequently Asked Questions About SRPT
What is the SRPT stock forecast?
Consensus analyst estimates put Sarepta Therapeutics's EPS at $3.95 for the fiscal year ending Dec 31, 2026, on revenue of $1.86B. The consensus rating from 24 analysts is Hold.
How do analysts rate SRPT stock?
Of 24 analysts covering Sarepta Therapeutics, 0 rate it Strong Buy, 7 Buy, 12 Hold, 3 Sell and 2 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from SRPT next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $3.95, with estimates from $2.05 to $5.03 from 11 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $1.48, with estimates from -$0.30 to $3.47 from 11 analysts.
What revenue do analysts expect from Sarepta Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $1.86B, with estimates from $1.80B to $1.89B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.38B, with estimates from $856.94M to $1.79B.
How many analysts cover SRPT?
24 analysts rate Sarepta Therapeutics stock, and 11 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
SRPT pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors